Compare Moderna, Inc. (MRNA) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tenet Healthcare Corporation — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while Tenet Healthcare Corporation trades at $267.21 (market cap $20.89B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | THC | |
|---|---|---|
Market Cap | $24.18B | $20.89B |
Sector | Health | Health |
52-Week High | $81.80 | $262.63 |
52-Week Low | $22.36 | $161.37 |
Enterprise Value | $20.33B | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Tenet Healthcare (THC) trades at $266.15, up 2.39% today, with strong technical momentum including a golden cross formation. The stock shows robust fundamentals with a P/E of 10.03, net income margin of 9.9%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with EPS of $6.12 versus $4.26 estimate, driving positive analyst sentiment.
Outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target, though investors should monitor policy headwinds in healthcare and the stock's proximity to 52-week highs. The company's ambulatory growth and raised 2026 guidance support continued upside potential despite net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
